

Zoltan Kalo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1322788/publications.pdf>

Version: 2024-02-01

185
papers

3,235
citations

201674

27
h-index

189892

50
g-index

196
all docs

196
docs citations

196
times ranked

3149
citing authors

#	ARTICLE	IF	CITATIONS
1	Can cost-effectiveness principles be ignored in urgent times?. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 7-9.	1.4	3
2	Healthcare financing in Egypt: a systematic literature review.. <i>Journal of the Egyptian Public Health Association</i> , The, 2022, 97, 1.	2.5	19
3	POSB253 Development of a Multi Criteria Decision Analysis (MCDA) Tool for Medical Devices National Procurement in Egypt. <i>Value in Health</i> , 2022, 25, S176.	0.3	0
4	Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 291-303.	2.1	1
5	Burden of Chronic Heart Failure in Romania. <i>Healthcare (Switzerland)</i> , 2022, 10, 107.	2.0	6
6	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. <i>Health Economics (United Kingdom)</i> , 2022, 31, 179-194.	1.7	6
7	A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, 10.	2.4	2
8	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. <i>Health Economics (United Kingdom)</i> , 2022, , .	1.7	5
9	Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications. <i>Frontiers in Pharmacology</i> , 2022, 13, 815029.	3.5	7
10	Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 905-913.	1.4	7
11	Retrospective cost-utility analysis of the Non-typhoidal Salmonella control programme in Hungary. <i>Food Control</i> , 2021, 120, 107529.	5.5	2
12	The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?. <i>Health Policy</i> , 2021, 125, 593-601.	3.0	11
13	Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. <i>European Journal of Health Economics</i> , 2021, 22, 1253-1273.	2.8	13
14	Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. <i>European Journal of Cancer Care</i> , 2021, 30, e13473.	1.5	2
15	Patient and Payer Preferences for Additional Value Criteria. <i>Frontiers in Pharmacology</i> , 2021, 12, 690021.	3.5	7
16	Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE. <i>Frontiers in Pharmacology</i> , 2021, 12, 680737.	3.5	10
17	PCN141 Systematic Literature Review of Health Economic Models Developed for Myeloma. <i>Value in Health</i> , 2021, 24, S45.	0.3	0
18	PNS77 Transferring Health Technology Assessments from EARLY Adopter to Late Adopter Countries: Recommendations for the Implementation of CED Schemes in Central and Eastern European Countries. <i>Value in Health</i> , 2021, 24, S187.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Proposal for capturing patient experience through extended value frameworks of health technologies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 936-947.	0.9	4
20	Regulatory and HTA early dialogues in medical devices. <i>Health Policy</i> , 2021, 125, 1322-1329.	3.0	8
21	Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 42.	1.5	5
22	Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 57.	1.5	7
23	Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan. <i>Value in Health Regional Issues</i> , 2021, 25, 126-134.	1.2	7
24	Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102264.	7.7	29
25	Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 653-659.	1.4	8
26	Current and future perspectives for the implementation of health technology assessment in Romania. <i>Health Policy and Technology</i> , 2020, 9, 45-52.	2.5	8
27	Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries – A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses. <i>Frontiers in Pharmacology</i> , 2020, 11, 1203.	3.5	7
28	Barriers and facilitators of exploiting the potential of value-added medicines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 229-236.	1.4	7
29	PPM6 EARLY PHASE ECONOMIC EVALUATION OF NEW GENERATION SEQUENCE DIAGNOSTICS IN MULTIPLE MYELOMA. <i>Value in Health</i> , 2020, 23, S326-S327.	0.3	1
30	Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2020, 11, 845.	3.5	8
31	The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 321-330.	1.4	14
32	Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status. <i>Frontiers in Pharmacology</i> , 2020, 11, 15.	3.5	37
33	European cooperation in health technology assessment implementation: the perspective of Central and Eastern European countries. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 599-602.	1.4	6
34	Implementation of palliative care consult Service in Hungary – integration barriers and facilitators. <i>BMC Palliative Care</i> , 2020, 19, 41.	1.8	11
35	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9
36	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. <i>Croatian Medical Journal</i> , 2020, 61, 252-259.	0.7	5

#	ARTICLE	IF	CITATIONS
37	PNS108 Proposal for a Core Evaluation Framework of Value Added Medicines. Value in Health, 2020, 23, S659-S660.	0.3	0
38	PNS55 Managed Entry Agreements in Egypt: Current Practices and Future Preferences. Value in Health, 2020, 23, S652-S653.	0.3	0
39	How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia. Frontiers in Pharmacology, 2019, 10, 664.	3.5	7
40	PBI24 UTILIZATION AND SWITCHING PATTERNS OF BIOLOGICAL MEDICINES IN THE INDICATIONS OF INFlixIMAB BEFORE AND AFTER PATIENT EXPIRY. Value in Health, 2019, 22, S51.	0.3	1
41	PNS172 COMPARISON OF CURRENT AND PREFERRED STATUS OF HTA IMPLEMENTATION IN JORDAN. Value in Health, 2019, 22, S314.	0.3	0
42	PNS179 HTA IMPLEMENTATION IN MIDDLE EAST AND NORTH AFRICA: COMPARISON OF CURRENT AND PREFERRED STATUS. Value in Health, 2019, 22, S315-S316.	0.3	2
43	External Reference Pricing for Pharmaceuticals – A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage. Value in Health Regional Issues, 2019, 19, 122-131.	1.2	25
44	Is there a fair allocation of healthcare research funds by the European Union?. PLoS ONE, 2019, 14, e0207046.	2.5	8
45	Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives. International Journal of Technology Assessment in Health Care, 2019, 35, 393-400.	0.5	7
46	Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. Health Policy and Technology, 2019, 8, 84-91.	2.5	7
47	Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review. Antiviral Therapy, 2019, 24, 247-259.	1.0	5
48	Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology. Health Policy, 2019, 123, 630-634.	3.0	9
49	Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. Health Policy, 2019, 123, 713-720.	3.0	7
50	Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait. Journal of Pharmaceutical Policy and Practice, 2019, 12, 9.	2.4	12
51	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. BMC Health Services Research, 2019, 19, 131.	2.2	10
52	Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. Journal of Comparative Effectiveness Research, 2019, 8, 195-204.	1.4	92
53	Shedding light on the HTA consultancy market: Insights from Poland. Health Policy, 2019, 123, 1237-1243.	3.0	4
54	How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 627-632.	1.4	10

#	ARTICLE	IF	CITATIONS
55	<p>Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence</p>. Cancer Management and Research, 2019, Volume 11, 9849-9861.	1.9	19
56	Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 105-113.	1.4	11
57	When health technology assessment is confidential and experts have no power: the case of Hungary. Health Economics, Policy and Law, 2019, 14, 162-181.	1.8	18
58	Transparency in practice: Evidence from â€˜verification analysesâ€™ issued by the Polish Agency for Health Technology Assessment in 2012â€“2015. Health Economics, Policy and Law, 2019, 14, 182-204.	1.8	9
59	MagyarorszÃ¡gon becsÃ¡lt Ã©letminÃ¡sÃ©ggel korrigÃ¡lt Ã©letÃ©vnyeresÃ©g lehetÃ©sÃ©ge a negatÃ¡v tÃ¡rnyezetÃ©s szkizofrÃ©niÃ¡ban kariprazin alkalmazÃ¡sa esetÃ©n. Lege Artis Medicinae, 2019, 29, 467-475.	0.1	0
60	A utility of model input uncertainty analysis in transferring tobacco controlâ€™related economic evidence to countries with scarce resources: results from the EQUIPT study. Addiction, 2018, 113, 42-51.	3.3	5
61	An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets. Value in Health Regional Issues, 2018, 16, 9-13.	1.2	15
62	Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health, 2018, 21, 493-500.	0.3	75
63	Direct healthcare cost of schizophrenia â€™ European overview. European Psychiatry, 2018, 48, 79-92.	0.2	31
64	Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis. Orphanet Journal of Rare Diseases, 2018, 13, 67.	2.7	16
65	Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. European Journal of Cancer Care, 2018, 27, e12430.	1.5	47
66	PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIES. Value in Health, 2018, 21, S180.	0.3	1
67	Considerations for External Reference Pricing Practices in Developing Countries Learned from Experiences Across Europe and Other Developed Countries. Value in Health, 2018, 21, S45.	0.3	0
68	Value-Based Decisions for Off-Patent Pharmaceuticals in Developing Countries â€™ A Pilot Study Using Multi-Criteria Decision Analysis for Tenders in Indonesia. Value in Health, 2018, 21, S45.	0.3	0
69	PCN361 - HEALTH ECONOMIC VALUE PROPOSITIONS FOR SUBCUTANEOUS TRASTUZUMAB AND THEIR TRANSFERABILITY TO CENTRAL-EASTERN EUROPEAN COUNTRIES. Value in Health, 2018, 21, S75.	0.3	0
70	PRM131 - HEPATITIS C VIRUS ELIMINATION AND ERADICATION MODELS: A SYSTEMATIC LITERATURE REVIEW. Value in Health, 2018, 21, S378.	0.3	0
71	Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals â€™ an application on improving tender decision making in Indonesia. BMC Health Services Research, 2018, 18, 1003.	2.2	23
72	PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIES. Value in Health, 2018, 21, S201.	0.3	0

#	ARTICLE	IF	CITATIONS
73	A systematic review of the indirect costs of schizophrenia in Europe. <i>European Journal of Public Health</i> , 2018, 28, 1043-1049.	0.3	26
74	PND124 - HUMANISTIC AND ECONOMIC BURDEN OF PROGRESSIVE SUPRANUCLEAR PALSY: A SYSTEMATIC LITERATURE REVIEW. <i>Value in Health</i> , 2018, 21, S349-S350.	0.3	0
75	The European challenges of funding orphan medicinal products. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 184.	2.7	34
76	Results of a Targeted Literature Review on the Cost-Effectiveness Models Developed for Retinopathy of Prematurity. <i>Value in Health</i> , 2018, 21, S221.	0.3	0
77	Fair global drug pricing. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 581-583.	1.4	5
78	The value of a child born in the European Union. <i>Acta Oeconomica</i> , 2018, 68, 295-309.	0.5	0
79	Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	23
80	Biosimilar Infliximab Utilization After Patent Expiry: The Case of Colitis Ulcerosa and Rheumatoid Arthritis in Hungary. <i>Value in Health</i> , 2018, 21, S95-S96.	0.3	1
81	Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. <i>BMC Health Services Research</i> , 2018, 18, 115.	2.2	2
82	Guidance toward the implementation of multicriteria decision analysis framework in developing countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 585-592.	1.4	24
83	Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2018, 9, 795.	3.5	13
84	The implications of external price referencing on pharmaceutical list prices in Europe. <i>Health Policy and Technology</i> , 2018, 7, 243-250.	2.5	13
85	Policy objective of generic medicines from the investment perspective: The case of clopidogrel. <i>Health Policy</i> , 2017, 121, 558-565.	3.0	10
86	Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. <i>Value in Health Regional Issues</i> , 2017, 13, 1-6.	1.2	20
87	OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 333-338.	0.5	8
88	HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status. <i>Value in Health Regional Issues</i> , 2017, 14, 20-27.	1.2	19
89	A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 283-292.	1.4	1
90	Osteoporotic fractures may impair life as much as the complications of diabetes. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 1375-1380.	1.8	12

#	ARTICLE	IF	CITATIONS
91	Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1345580.	1.5	33
92	Is there a reason for concern or is it just hype? â€” A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 915-926.	3.1	38
93	Overview on Patient Centricity in Cancer Care. <i>Frontiers in Pharmacology</i> , 2017, 8, 698.	3.5	13
94	Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. <i>Frontiers in Pharmacology</i> , 2017, 8, 946.	3.5	2
95	Impact of National Criteria and Healthcare System Characteristics on Access to Biologic Dmards in Rheumatoid Arthritis In Europe. <i>Value in Health</i> , 2016, 19, A547-A548.	0.3	0
96	Is External Reference Pricing A Threat to International Equal Affordability?. <i>Value in Health</i> , 2016, 19, A759-A760.	0.3	0
97	The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 483-488.	1.4	3
98	Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 72.	2.7	49
99	DRIVING UHC In Emering EMERGING: AN EGYPTIAN CASE. <i>Value in Health</i> , 2016, 19, A290.	0.3	1
100	HTA Implementation Roadmap in Central and Eastern European Countries. <i>Health Economics (United Kingdom)</i> , 2016, 30, 107-120.	1.7	62
101	Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 710-729.	4.0	8
102	Mapping of The Biosimilar Drug Policy in 10 Central Eastern European Countries. <i>Value in Health</i> , 2016, 19, A504-A505.	0.3	1
103	Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. <i>Health Policy and Planning</i> , 2016, 32, czw133.	2.7	12
104	Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 15-16.	1.4	3
105	Multiple Criteria Decision Analysis for Health Care Decision Makingâ€”An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 1-13.	0.3	437
106	Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 23.	2.7	39
107	Multiple Criteria Decision Analysis for Health Care Decision Makingâ€”Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 125-137.	0.3	320
108	SELFIE, a novel Horizon2020 project on integrated care for multi-morbidity. <i>International Journal of Integrated Care</i> , 2016, 16, 304.	0.2	0

#	ARTICLE	IF	CITATIONS
109	REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. International Journal of Technology Assessment in Health Care, 2015, 31, 434-441.	0.5	15
110	CHALLENGES FACED IN TRANSFERRING ECONOMIC EVALUATIONS TO MIDDLE INCOME COUNTRIES. International Journal of Technology Assessment in Health Care, 2015, 31, 442-448.	0.5	27
111	Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 145-155.	1.4	7
112	Need for Multicriteria Evaluation of Generic Drug Policies. Value in Health, 2015, 18, 346-351.	0.3	35
113	Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 993-998.	1.4	29
114	Next steps to evidence-based food safety risk analysis: opportunities for health technology assessment methodology implementation. Studies in Agricultural Economics, 2015, 117, 155-161.	0.5	4
115	Medical and economic burden of influenza in the elderly population in central and eastern European countries. Human Vaccines and Immunotherapeutics, 2014, 10, 428-440.	3.3	27
116	Contribution of clinical trials to gross domestic product in Hungary. Croatian Medical Journal, 2014, 55, 446-451.	0.7	5
117	Benefits of investment into modern medicines in Central and Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 71-79.	1.4	11
118	EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. BMJ Open, 2014, 4, e006945.	1.9	29
119	Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. Value in Health Regional Issues, 2014, 4, 24-30.	1.2	7
120	Mapping the Nottingham Health Profile onto the Preference-Based EuroQol-5D Instrument for Patients with Diabetes. Value in Health Regional Issues, 2014, 4, 31-36.	1.2	5
121	The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 175, 75-81.	1.1	12
122	Investment Aspects of Generic Drug Policies in Countries With Severe Resource Constraints. Value in Health, 2014, 17, A500.	0.3	0
123	Cost-Effectiveness of The introduction of A National Adherence Program for Type 2 Diabetes In Hungary. Value in Health, 2014, 17, A358.	0.3	0
124	Economic Evaluation of Ulipristal Acetate for the Treatment of Patients With Moderate and Severe Symptoms of Uterine Fibroids in Romania. Value in Health, 2014, 17, A510.	0.3	1
125	Comparative Cost-Effectiveness Study of Modern Radiation Therapies in Hungary for Localized Prostate Cancer. Value in Health, 2014, 17, A636.	0.3	0
126	Implications Of External Price Referencing of Pharmaceuticals in Middle East Countries. Value in Health, 2014, 17, A409.	0.3	0

#	ARTICLE	IF	CITATIONS
127	The humanistic and economic burden of bulimia nervosa and binge eating disorder: A systematic literature review. Value in Health, 2014, 17, A213.	0.3	0
128	The long-term economic value of a new-born child comparison of the human capital and the lifetime investment approaches. Value in Health, 2014, 17, A185.	0.3	0
129	Cost-effectiveness of the introduction of a risk stratified population screening for type 2 diabetes in Hungary. Value in Health, 2014, 17, A259.	0.3	0
130	Transferability Of International Evidence On The Benefits Of Innovative Medicines Into Central Eastern European Countries. Value in Health, 2014, 17, A33.	0.3	0
131	Challenges Faced By Decision Makers From Middle Income Countries In Transferring Pharmacoeconomic Data And Analyses From Other Jurisdictions. Value in Health, 2014, 17, A26.	0.3	0
132	Differential pricing of new pharmaceuticals in lower income European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 735-741.	1.4	44
133	Pharmaceutical Spending Levels Across Europe – Consequences Of Current International Pricing Policies On Lower Income Countries. Value in Health, 2013, 16, A255.	0.3	0
134	Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary. Value in Health Regional Issues, 2013, 2, 264-266.	1.2	42
135	Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt. Value in Health Regional Issues, 2013, 2, 319-327.	1.2	46
136	Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa. Value in Health Regional Issues, 2013, 2, 169-170.	1.2	21
137	Mapping the cancer-specific EORTC QLQ-BR23 onto the preference-based EuroQol-5D instrument. , 2013, , 99-101.		1
138	Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 283-287.	1.4	16
139	PRM85 Internal Validation of the Syreon Diabetes Model. Value in Health, 2012, 15, A475.	0.3	2
140	Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health, 2012, 12, 924.	2.9	7
141	Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. BMC Health Services Research, 2012, 12, 332.	2.2	22
142	Modeling Cost-Effectiveness of Cervical Cancer Screening in Hungary. Value in Health, 2012, 15, 39-45.	0.3	11
143	PHP44 International Comparison of Pharmaceutical Expenditure in Middle Income Countries: Methodological Questions. Value in Health, 2012, 15, A21.	0.3	2
144	PHP27 Implementation of the Transparency Directive in Hungary: Special Focus on Time Limits for Pricing and Reimbursement Decisions. Value in Health, 2012, 15, A293.	0.3	0

#	ARTICLE	IF	CITATIONS
145	PHP31 The Value of Investigational Medical Products. Value in Health, 2012, 15, A294.	0.3	0
146	PHP96 Evidence Based Structural Reform in the Provision of Hospital Care: The Case Study of Merging Two Institutions in Hungary. Value in Health, 2012, 15, A305.	0.3	0
147	PIH24 Economic Evaluation of Ulipristal Acetate Tablets for the Treatment of Patients with Moderate and Severe Symptoms of Uterine Fibroids. Value in Health, 2012, 15, A540.	0.3	1
148	Modelling the burden of disease associated malnutrition. E-SPEN Journal, 2012, 7, e196-e204.	0.5	19
149	Pitfalls associated with the therapeutic reference pricing practice of asthma medication. BMC Pulmonary Medicine, 2012, 12, 35.	2.0	3
150	Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. European Journal of Cancer Care, 2012, 21, 442-449.	1.5	34
151	PCN121 Challenges in Conducting Pharmacoeconomic Analyses in Central and Eastern Europe – Case Study on Breast Cancer. Value in Health, 2011, 14, A456.	0.3	0
152	PSS17 Societal Burden of Blindness in Hungary. Value in Health, 2011, 14, A505.	0.3	0
153	PDB82 Development of a Health Economic Model to Compare the Prevention, Treatment and Management Strategies of Type 2 Diabetes. Value in Health, 2011, 14, A486-A487.	0.3	1
154	PCN116 TRANSFERABILITY OF NICE RECOMMENDATIONS FOR PHARMACEUTICAL THERAPIES IN ONCOLOGY TO CENTRAL-EASTERN EUROPEAN COUNTRIES. Value in Health, 2011, 14, A175.	0.3	0
155	PHP73 Government Reduces Public Pharmaceutical Expenditure in Hungary: Rational Decisions in Challenging Economic times?. Value in Health, 2011, 14, A346.	0.3	0
156	PHP83 The Economic Burden of Disease Related Malnutrition in Europe. Value in Health, 2011, 14, A348.	0.3	0
157	Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. British Journal of Pharmacology, 2010, 159, 1367-1373.	5.4	35
158	PCN103 COST-EFFECTIVENESS ANALYSIS OF ADDING HPV VACCINATION TO CERVICAL CANCER SCREENING PROGRAM IN HUNGARY. Value in Health, 2010, 13, A270-A271.	0.3	1
159	PDB24 DIRECT HEALTH CARE COSTS OF DIABETES MELLITUS IN HUNGARY. Value in Health, 2010, 13, A288.	0.3	1
160	PRS16 PITFALLS IN THERAPEUTIC REFERENCE PRICING PRACTICE OF THE MEDICATION OF ASTHMA. Value in Health, 2010, 13, A321.	0.3	0
161	PHP10 QUALITY ASSURANCE OF FOURTH HURDLE IN HUNGARY – A METHODOLOGICAL APPROACH. Value in Health, 2009, 12, A239.	0.3	1
162	PMH43 THE COST-EFFECTIVENESS OF QUETIAPINE XR IN THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN SCHIZOPHRENIA. Value in Health, 2009, 12, A358-A359.	0.3	0

#	ARTICLE	IF	CITATIONS
163	PHP32 COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT. <i>Value in Health</i> , 2008, 11, A372.	0.3	0
164	PHP17 HOW MANDATORY PRICE REDUCTION OF REIMBURSED PHARMACEUTICALS COULD RESULT IN INCREASED PHARMACEUTICAL EXPENDITURE?. <i>Value in Health</i> , 2008, 11, A34.	0.3	0
165	Expanding the Evidence Base in Transplantation: The Complementary Roles of Randomized Controlled Trials and Outcomes Research. <i>Transplantation</i> , 2008, 86, 18-25.	1.0	14
166	Does therapeutic reference pricing always result in cost-containment?. <i>Health Policy</i> , 2007, 80, 402-412.	3.0	23
167	PHP5 DOES ENTRY OF GENERIC DRUGS ALWAYS RESULT IN COST-CONTAINMENT? THE HUNGARIAN EVIDENCE. <i>Value in Health</i> , 2007, 10, A362.	0.3	0
168	PCV18 ECONOMIC BENEFIT OF IMPROVED PRESERVATION OF EXPLANTED ORGANS IN HEART TRANSPLANTATION. <i>Value in Health</i> , 2007, 10, A410-A411.	0.3	0
169	Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. <i>Clinical Transplantation</i> , 2005, 19, 122-129.	1.6	9
170	The Life-Years Saved by a Deceased Organ Donor. <i>American Journal of Transplantation</i> , 2005, 5, 2289-2296.	4.7	118
171	Cost-Effectiveness of Organ Donation: Evaluating Investment into Donor Action and Other Donor Initiatives. <i>American Journal of Transplantation</i> , 2004, 4, 569-573.	4.7	94
172	An Economic Model of 2-Hour Post-Dose Cyclosporin Monitoring in Renal Transplantation. <i>Pharmacoeconomics</i> , 2004, 22, 621-632.	3.3	8
173	PUK8 2-HOUR POST DOSE (C2) MONITORING VERSUS TROUGH (C0) MONITORING OF NEORAL: AN ECONOMIC EVALUATION. <i>Value in Health</i> , 2004, 7, 800.	0.3	0
174	Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. <i>Diabetes and Metabolism</i> , 2004, 30, 549-556.	2.9	76
175	RESOURCE USE AND TREATMENT COSTS AFTER KIDNEY TRANSPLANTATION: IMPACT OF DEMOGRAPHIC FACTORS, COMORBIDITIES, AND COMPLICATIONS. <i>Transplantation</i> , 2004, 77, 1545-1550.	1.0	52
176	Cost-benefit approach in evaluating investment into donor action: the German case. <i>Transplant International</i> , 2003, 16, 321-326.	1.6	21
177	Economic aspects of renal transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 1223-1226.	0.6	16
178	Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. <i>Health Policy</i> , 2003, 63, 49-61.	3.0	13
179	Economic evaluation of everolimus vs. azathioprine as part of triple immunosuppressive therapy in a phase III de novo heart transplant trial. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, S167.	0.6	1
180	The Cost Effectiveness of Apligraf?? Treatment of Diabetic Foot Ulcers. <i>Pharmacoeconomics</i> , 2003, 21, 1171-1183.	3.3	63

#	ARTICLE	IF	CITATIONS
181	Meta-Analysis of Basiliximab for Immunoprophylaxis in Renal Transplantation. <i>BioDrugs</i> , 2003, 17, 271-279.	4.6	34
182	The expanded criterial donor dilemma in cadaveric renal transplantation. <i>Transplantation</i> , 2003, 75, 1940-1945.	1.0	107
183	Cost-benefit approach in evaluating investment into donor action: the German case. <i>Transplant International</i> , 2003, 16, 321-6.	1.6	11
184	Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary. <i>Progress in Transplantation</i> , 2001, 11, 188-193.	0.7	19
185	Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	12